Cleaning Validation: Quantitative Estimation of Atorvastatin in Production Area

References

1. 1.↵
   FDA. Guide to inspections of validation of cleaning processes, September 1993.
2. 2.↵
   Guide to Inspections of Validation of Cleaning Processes, Reference Material for FDA Investigators and Personnel; FDA Office of Regulatory Affairs: Washington, DC, 2011.
3. 3.↵
   PDA Technical Report No. 29. Points to consider for cleaning validation. PDA J. Pharm. Sci. Technol. 1998, 52 (6), 1–23.

   OpenUrlPubMed
4. 4.↵
   Cleaning Validation Guidelines—Good Manufacturing Practice, Health Products and Food Branch Inspectorate, Canada, 2004.
5. 5.↵
   Active Pharmaceutical Ingredient Committee. Guidance on Aspects of Cleaning Validation in Active Pharmaceutical Ingredient Plants, September 2000.
6. 6.↵
   1. Fazio T. T.,
   2. Singh A. K.,
   3. Kedor-Hackmann E. R.,
   4. Santoro M. I.

   Quantitative determination and sampling of azathioprine residues for cleaning validation in production area. J. Pharm. Biomed. Anal. 2007, 43 (4), 1495–1498.

   OpenUrlPubMed
7. 7.↵
   1. Klinkenberg R.,
   2. Streel B.,
   3. Ceccato A.

   Development and validation of a liquid chromatographic method for the determination of the amlodipine residues on manufacturing equipment surfaces. J. Pharm. Biomed. Anal. 2003, 32 (2), 345–352.

   OpenUrlPubMed
8. 8.↵
   1. Fourman G. L.,
   2. Mullen M. V.

   Determining cleaning validation acceptance limits for pharmaceutical manufacturing operations. Pharm. Technol. 1993, 17 (4), 54–60.

   OpenUrl
9. 9.↵
   1. Shabir G. A.

   Equipment cleaning validation: developing an HPLC method to determine contamination residues on equipment surfaces. Am. Pharm. Rev. 2008, 11 (4), 16–22.

   OpenUrl
10. 10.↵
    Indian Pharmacopoeia, 6th ed.; Ministry of Family and Health Welfare: New Delhi, India, 2010; Vol. 2, p 849.

    OpenUrl
11. 11.↵
    1. Rang H. P.,
    2. Dale M. M.,
    3. Ritter J. M.,
    4. Moore P. K.

    Pharmacology, 5th ed.; Elsevier (A Division of Reed Elsevier India Private Limited): New Delhi, India, 2006; p 310.
12. 12.↵
    1. Altuntas T. G.,
    2. Erk N.

    Liquid chromatographic determination of atorvastatin in bulk drug, tablets, and human plasma. J. Liq. Chrom. Rel. Technol. 2004, 27 (1), 83–93.

    OpenUrl
13. 13.↵
    1. Ertürk S.,
    2. Sevinç Aktaş E.,
    3. Ersoy L.,
    4. Fiçicioğlu S.

    An HPLC method for determination of atorvastatin and its impurities in bulk drug and tablets. J. Pharm. Biomed. Anal. 2003, 33 (5), 1017–1023.

    OpenUrlCrossRefPubMed
14. 14.↵
    1. Sharaf El-Din M. M. K.,
    2. Salama F. M. M.,
    3. Nassar M. W. I.,
    4. Attia K. A. M.,
    5. Kaddah M. M. Y.

    Validated spectrofluorimetric method for the determination of atorvastatin in pharmaceutical preparations. J. Pharm. Anal. 2012, 22 (3), 200–205.

    OpenUrl
15. 15.↵
    1. Jamshidi A.,
    2. Nateghi A. R.

    HPTLC determination of atorvastatin in plasma. Chromatographia. 2007, 65 (11–12), 763–766.

    OpenUrl
16. 16.↵
    1. Herman M.,
    2. Christensen H.,
    3. Reubsaet J. L.

    Determination of atorvastatin and metabolites in human plasma with solid-phase extraction followed by LC-tandem MS. Anal. Bioanal. Chem. 2005, 382 (5), 1242–1249.

    OpenUrlCrossRefPubMed
17. 17.↵
    1. Queralt M.,
    2. García-Montoya E.,
    3. Pérez-Lozano P.,
    4. Suñé-Negre J. M.,
    5. Miñarro M.,
    6. Ticó J. R.

    Total organic carbon (VCSN and VWP) and HPLC analysis for cleaning validation in a pharmaceutical pilot plant. PDA J. Pharm. Sci. Technol. 2009, 63 (1), 42–50.

    OpenUrlAbstract/FREE Full Text
18. 18.↵
    1. Aki M. A.,
    2. Ahmed M. A.,
    3. Ramadan A.

    Validation of an HPLC-UV method for the determination of ceftriaxone sodium residues on stainless steel surface of pharmaceutical manufacturing equipments. J. Pharm. Biomed. Anal. 2012, 55 (2), 247–252.

    OpenUrl
19. 19.↵
    1. Nozal M. J.,
    2. Bernal L.,
    3. Jiménez J. J.,
    4. Martín M. T.,
    5. Diez F. J.

    Development and validation of liquid chromatographic method for determination of lacidipine residues on surfaces in the manufacture of pharmaceuticals. J. Chromatogr., A 2004, 1024 (1–2), 115–122.

    OpenUrlPubMed
20. 20.↵
    ICH Harmonized Tripartite Guideline, Q2A. Text on Validation of Analytical Procedures, October 1994.
21. 21.↵
    1. Chudzik G. M.

    General guide to recovery studies using swab sampling methods for cleaning validation. J. Validation Technol. 1998, 5 (1), 77–81.

    OpenUrl
22. 22.↵
    1. Yang P.,
    2. Burson K.,
    3. Feder D.,
    4. Macdonald F.

    Method development of swab sampling for cleaning validation of a residue active pharmaceutical ingredient. Pharm. Technol. 2005, 29 84–94.

    OpenUrl
23. 23.↵
    1. Boca M. B.,
    2. Apostolides Z.,
    3. Pretorios E.

    A validated HPLC method for determination residues of a dual active ingredients anti-malarial drug on manufacturing equipment surfaces. J. Pharm. Biomed. Anal. 2005, 37 (3), 461–468.

    OpenUrlPubMed
24. 24.↵
    1. Lambropoulos J.,
    2. Spanos G. A.,
    3. Lazaridis N. V.

    Development and validation of an HPLC assay for fentanyl, alfentanil, and sufentanil in swab samples. J. Pharm. Biomed. Anal. 2000, 23 (2–3), 421–428.

    OpenUrlPubMed
25. 25.↵
    1. Dubey N.,
    2. Dubey N.,
    3. Mandhanya M.,
    4. Jain D. K.

    Cleaning level acceptance criteria and HPLC-DAD method validation for the determination of nabumetone residues on manufacturing equipment using swab sampling. J. Pharm. Anal. 2012, 2 (6), 478–483.

    OpenUrl